Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

NCT02216084 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

Interventions

DRUG: Recombinant ADAMTS13

Sponsor

Baxalta now part of Shire